Business
In this episode of Denatured, you’ll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We’ll discuss next-generation obesity solutions tackling GLP-1’s muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy.
FEATURED STORIES
An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Adagio Therapeutics has appointed current COO David Hering as interim CEO, replacing Tillman Gerngross, Ph.D., who communicated his intention to resign in mid-February.
Jeffrey D. Marrazzo, the co-founder of Spark Therapeutics, is stepping down as CEO of the company. The current COO, Ron Philip, will replace him.
The arrangement provides the opportunity for LJI faculty and postdocs to make a more immediate impact on drug development while offering a different perspective to KKNA.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Intellia announced a lease agreement to develop a 140,000 square-foot manufacturing facility in Waltham, MA, while Moderna and Thermo Fisher Scientific sign a long-term deal.
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
Veru’s enobosarm shows good proof of concept data even when 90% of patients have failed first-line therapies.
Robert LaCaze is taking over the reins of Mnemo Therapeutics with the goal of overcoming key challenges in CAR-T therapies and driving the company’s lead assets into the clinic.
Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders.
The companies will design and develop targeted gene therapies for a liver-directed rare disease program and conduct additional studies for central nervous system-directed rare disease programs.